Portia M Manngo1, Andrea Gutschmidt1, Candice I Snyders1, Hygon Mutavhatsindi1, Charles M Manyelo1, Nonjabulo S Makhoba1, Petri Ahlers1, Andriette Hiemstra1, Kim Stanley1, Shirley McAnda1, Martin Kidd2, Stephanus T Malherbe2, Gerhard Walzl1, Novel N Chegou3. 1. DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Po Box 241, Cape Town 8000, South Africa. 2. Centre for Statistical Consultation, Department of Statistics and Actuarial Sciences, Stellenbosch University, Cape Town, South Africa. 3. DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Po Box 241, Cape Town 8000, South Africa. Electronic address: novel@sun.ac.za.
Abstract
BACKGROUND: There is an urgent need for new tools for the diagnosis of TB. We evaluated the usefulness recently described host biomarkers in supernatants from the newest generation of the QuantiFERON test (QuantiFERON Plus) as tools for the diagnosis of active TB. METHODS: We recruited individuals presenting at primary health care clinics in Cape Town, South Africa with symptoms requiring investigation for TB disease, prior to the establishment of a clinical diagnosis. Participants were later classified as TB or other respiratory diseases (ORD) based on the results of clinical and laboratory tests. Using a multiplex platform, we evaluated the concentrations of 37 host biomarkers in QuantiFERON Plus supernatants from study participants as tools for the diagnosis of TB. RESULTS: Out of 120 study participants, 35(29.2%) were diagnosed with active TB, 69(57.5%) with ORD whereas 16(13.3%) were excluded. 14(11.6%) of the study participants were HIV infected. Although individual host markers showed potential as diagnostic candidates, the main finding of the study was the identification of a six-marker biosignature in unstimulated supernatants (Apo-ACIII, CXCL1, CXCL9, CCL8, CCL-1, CD56) which diagnosed TB with sensitivity and specificity of 73.9%(95% CI; 51.6-87.8) and 87.6%(95% CI; 77.2-94.5), respectively, after leave-one-out cross validation. Combinations between TB-antigen specific biomarkers also showed potential (sensitivity of 77.3% and specificity of 69.2%, respectively), with multiple biomarkers being significantly different between TB patients, Quantiferon Plus Positive and Quantiferon Plus negative individuals with ORD, regardless of HIV status. CONCLUSIONS: Biomarkers detected in QuantiFERON Plus supernatants may contribute to adjunctive diagnosis of TB.
BACKGROUND: There is an urgent need for new tools for the diagnosis of TB. We evaluated the usefulness recently described host biomarkers in supernatants from the newest generation of the QuantiFERON test (QuantiFERON Plus) as tools for the diagnosis of active TB. METHODS: We recruited individuals presenting at primary health care clinics in Cape Town, South Africa with symptoms requiring investigation for TB disease, prior to the establishment of a clinical diagnosis. Participants were later classified as TB or other respiratory diseases (ORD) based on the results of clinical and laboratory tests. Using a multiplex platform, we evaluated the concentrations of 37 host biomarkers in QuantiFERON Plus supernatants from study participants as tools for the diagnosis of TB. RESULTS: Out of 120 study participants, 35(29.2%) were diagnosed with active TB, 69(57.5%) with ORD whereas 16(13.3%) were excluded. 14(11.6%) of the study participants were HIV infected. Although individual host markers showed potential as diagnostic candidates, the main finding of the study was the identification of a six-marker biosignature in unstimulated supernatants (Apo-ACIII, CXCL1, CXCL9, CCL8, CCL-1, CD56) which diagnosed TB with sensitivity and specificity of 73.9%(95% CI; 51.6-87.8) and 87.6%(95% CI; 77.2-94.5), respectively, after leave-one-out cross validation. Combinations between TB-antigen specific biomarkers also showed potential (sensitivity of 77.3% and specificity of 69.2%, respectively), with multiple biomarkers being significantly different between TBpatients, Quantiferon Plus Positive and Quantiferon Plus negative individuals with ORD, regardless of HIV status. CONCLUSIONS: Biomarkers detected in QuantiFERON Plus supernatants may contribute to adjunctive diagnosis of TB.
Authors: Novel N Chegou; Kim G P Hoek; Magdalena Kriel; Robin M Warren; Thomas C Victor; Gerhard Walzl Journal: Expert Rev Anti Infect Ther Date: 2011-04 Impact factor: 5.091
Authors: A Trajman; M Pai; K Dheda; R van Zyl Smit; A A Zwerling; R Joshi; S Kalantri; P Daley; D Menzies Journal: Eur Respir J Date: 2008-05 Impact factor: 16.671
Authors: Novel N Chegou; Gerhard Walzl; Chris T Bolliger; Andreas H Diacon; Michel M van den Heuvel Journal: Respiration Date: 2008-04-24 Impact factor: 3.580
Authors: Novel N Chegou; Gillian F Black; Andre G Loxton; Kim Stanley; Paulin N Essone; Michel R Klein; Shreemanta K Parida; Stefan H E Kaufmann; T Mark Doherty; Annemieke H Friggen; Kees L Franken; Tom H Ottenhoff; Gerhard Walzl Journal: BMC Infect Dis Date: 2012-01-20 Impact factor: 3.090
Authors: Kathryn L Kellar; Jennifer Gehrke; Stephen E Weis; Aida Mahmutovic-Mayhew; Blachy Davila; Margan J Zajdowicz; Robin Scarborough; Philip A LoBue; Alfred A Lardizabal; Charles L Daley; Randall R Reves; John Bernardo; Brandon H Campbell; William C Whitworth; Gerald H Mazurek Journal: PLoS One Date: 2011-11-21 Impact factor: 3.240
Authors: Novel N Chegou; Paulin N Essone; Andre G Loxton; Kim Stanley; Gillian F Black; Gian D van der Spuy; Paul D van Helden; Kees L Franken; Shreemanta K Parida; Michel R Klein; Stefan H E Kaufmann; Tom H M Ottenhoff; Gerhard Walzl Journal: PLoS One Date: 2012-06-05 Impact factor: 3.240
Authors: Novel N Chegou; Anne K Detjen; Lani Thiart; Elisabetta Walters; Anna M Mandalakas; Anneke C Hesseling; Gerhard Walzl Journal: PLoS One Date: 2013-05-15 Impact factor: 3.240
Authors: Joel Fleury Djoba Siawaya; Teri Roberts; Chantal Babb; Gillian Black; Hawa Jande Golakai; Kim Stanley; Nchinya Bennedict Bapela; Eileen Hoal; Shreemanta Parida; Paul van Helden; Gerhard Walzl Journal: PLoS One Date: 2008-07-02 Impact factor: 3.240
Authors: Thomas C Morris; Clive J Hoggart; Novel N Chegou; Martin Kidd; Tolu Oni; Rene Goliath; Katalin A Wilkinson; Hazel M Dockrell; Lifted Sichali; Louis Banda; Amelia C Crampin; Neil French; Gerhard Walzl; Michael Levin; Robert J Wilkinson; Melissa S Hamilton Journal: Front Immunol Date: 2021-02-25 Impact factor: 7.561
Authors: Prem Perumal; Mohamed Bilal Abdullatif; Harriet N Garlant; Isobella Honeyborne; Marc Lipman; Timothy D McHugh; Jo Southern; Ronan Breen; George Santis; Kalaiarasan Ellappan; Saka Vinod Kumar; Harish Belgode; Ibrahim Abubakar; Sanjeev Sinha; Seshadri S Vasan; Noyal Joseph; Karen E Kempsell Journal: Front Immunol Date: 2021-03-16 Impact factor: 7.561